Avoro Capital Advisors LLC Increases Stake in Krystal Biotech, Inc. $KRYS

Avoro Capital Advisors LLC raised its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,888,888 shares of the company’s stock after acquiring an additional 111,111 shares during the quarter. Krystal Biotech comprises 6.8% of Avoro Capital Advisors LLC’s portfolio, making the stock its 5th largest position. Avoro Capital Advisors LLC owned approximately 0.10% of Krystal Biotech worth $712,226,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KRYS. Royal Bank of Canada boosted its stake in Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after acquiring an additional 964 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after purchasing an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after purchasing an additional 688 shares in the last quarter. Empowered Funds LLC bought a new position in shares of Krystal Biotech during the first quarter worth $218,000. Finally, Cetera Investment Advisers boosted its position in shares of Krystal Biotech by 107.9% during the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after purchasing an additional 2,255 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Trading Down 0.4%

KRYS opened at $323.37 on Wednesday. The stock has a market capitalization of $9.53 billion, a P/E ratio of 43.23 and a beta of 0.53. Krystal Biotech, Inc. has a 12 month low of $127.99 and a 12 month high of $331.49. The firm’s fifty day simple moving average is $290.96 and its 200 day simple moving average is $269.76.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, equities research analysts predict that Krystal Biotech, Inc. will post 7.83 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on KRYS. HC Wainwright lifted their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Guggenheim lifted their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Jefferies Financial Group lifted their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Evercore reissued an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 5th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $329.78.

Insider Buying and Selling at Krystal Biotech

In related news, EVP John Charles Thomas sold 642 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.